Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.

Jubilee BrownAustin MillerLaura L HolmanFloor BackesChrista NagelDavid BenderDavid S MillerMatthew A PowellShannon N WestinAlbert BonebrakeCarolyn Y MullerAngeles Alvarez SecordErin CraneJohn SchorgeWilliam P TewAnil K SoodMichael A BookmanCarol AghajanianDavid M Gershenson

Published in: Gynecologic oncology (2024)

The study met its pre-specified criterion for stopping early for futility and so failed to demonstrate non-inferiority of PC versus BEP in ovarian SCSTs, in a non-inferiority test with a hazard ratio margin of 1.1. Both PC and BEP may be considered in patients with advanced/recurrent SCST.

Keyphrases

newly diagnosed
palliative care
randomized controlled trial
tyrosine kinase
phase ii study
pulmonary fibrosis
radiation therapy
endometrial cancer